51165-05-0

Basic information

• Product Name: SUBSTANCE P (7-11)
• Synonyms: SUBSTANCE P (7-11);SUBSTANCE P FRAGMENT 7-11;PHE-PHE-GLY-LEU-MET-NH2;PENTA-SUBSTANCE P;FFGLM-NH2;H-PHE-PHE-GLY-LEU-MET-NH2;SUBSTANCE P FRAGMENT 7-11 ACETATE);L-Phe-L-Phe-Gly-L-Leu-L-Met-NH2
• CAS NO: 51165-05-0
• Molecular Formula: C₃₁H₄₄N₆O₅S
• Molecular Weight: 612.78
• Product Categories: Peptide
• Mol File: 51165-05-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 1003.3°C at 760 mmHg
• Flash Point: 560.6°C
• Appearance: /
• Density: 1.207g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: -15°C
• PKA: 13.26±0.46(Predicted)
• CAS DataBase Reference: SUBSTANCE P (7-11)(CAS DataBase Reference)
• NIST Chemistry Reference: SUBSTANCE P (7-11)(51165-05-0)
• EPA Substance Registry System: SUBSTANCE P (7-11)(51165-05-0)

Safety Data

• Hazardous Substances Data: 51165-05-0(Hazardous Substances Data)

Usage

General Description

Substance P (7-11) is a fragment of the neuropeptide Substance P, a neurotransmitter involved in pain perception, stress responses, and tissue repair. Composed of five specific amino acids from the full Substance P molecule (amino acids 7-11), it is known to have biological activity. Although its specific functions are not completely understood, it is thought to interact with NK1 and NK2 receptors associated with substance P. The Substance P (7-11) fragment is utilized in scientific research to study the mechanisms of the neuropeptide system and its involvement in various physiological and pathological processes.

InChI:InChI=1/C31H44N6O5S/c1-20(2)16-25(31(42)36-24(28(33)39)14-15-43-3)35-27(38)19-34-30(41)26(18-22-12-8-5-9-13-22)37-29(40)23(32)17-21-10-6-4-7-11-21/h4-13,20,23-26H,14-19,32H2,1-3H3,(H2,33,39)(H,34,41)(H,35,38)(H,36,42)(H,37,40)/t23-,24-,25-,26-/m0/s1

Upstream product

• 2280-68-4 N-tert-butoxycarbonyl-L-leucyl-L-methioninamide 
• 66876-64-0 Boc-Phe-Phe-Gly-OMe 
• 82816-76-0 N-tert-butoxycarbonyl-L-phenylalanine-L-phenylalanine-glycine 
• 2131-00-2 leucyl-methionine amide hydrochloride 
• 7625-57-2 methyl 2-((2S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanamido)acetate 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 73148-99-9 N-t-Boc-Phe-Phe-Gly-Leu-Met-NH₂ 

Downstream Products

• 61123-13-5 pyroglutamyl-phenylalanyl-phenylalanine-glycyl-leucyl-methionine amide 
• 108744-20-3 C₄₉H₆₁N₁₁O₁₀S 
• 71890-55-6 (S)-2-[2-((S)-2-{(S)-2-[2-(4-Hydroxy-phenyl)-acetylamino]-3-phenyl-propionylamino}-3-phenyl-propionylamino)-acetylamino]-4-methyl-pentanoic acid ((S)-1-carbamoyl-3-methylsulfanyl-propyl)-amide 
• 119372-40-6 (S)-2-[2-((S)-2-{(S)-2-[2-(4-Fluoro-phenyl)-acetylamino]-3-phenyl-propionylamino}-3-phenyl-propionylamino)-acetylamino]-4-methyl-pentanoic acid ((S)-1-carbamoyl-3-methylsulfanyl-propyl)-amide 
• 119372-38-2 (S)-2-[2-((S)-2-{(S)-2-[2-(2-Hydroxy-phenyl)-acetylamino]-3-phenyl-propionylamino}-3-phenyl-propionylamino)-acetylamino]-4-methyl-pentanoic acid ((S)-1-carbamoyl-3-methylsulfanyl-propyl)-amide 
• 73149-11-8 (S)-2-[2-((S)-2-{(S)-2-[3-(4-Hydroxy-phenyl)-propionylamino]-3-phenyl-propionylamino}-3-phenyl-propionylamino)-acetylamino]-4-methyl-pentanoic acid ((S)-1-carbamoyl-3-methylsulfanyl-propyl)-amide 
• 119372-43-9 Boc-aminocaproyl-Phe-Phe-Gly-Leu-Met-NH₂ 
• 71890-50-1 Ac-Phe₂-Gly-Leu-Met-NH₂ 
• 88364-84-5 [(S)-3-((S)-2-{2-[(S)-2-((S)-2-Amino-3-phenyl-propionylamino)-3-phenyl-propionylamino]-acetylamino}-4-methyl-pentanoylamino)-3-carbamoyl-propyl]-dimethyl-sulfonium 
• 70328-33-5 Z-Gln-Phe-Phe-Gly-Leu-Met-NH₂ 
• 82155-83-7 6-Amino-hexanoic acid {(S)-1-[(S)-1-({[(S)-1-((S)-1-carbamoyl-3-methylsulfanyl-propylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl}-carbamoyl)-2-phenyl-ethylcarbamoyl]-2-phenyl-ethyl}-amide 
• 119372-41-7 Tyr-Phe-Phe-Gly-Leu-Met-NH₂ 
• 109003-57-8 Z-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ 
• 56104-22-4 pGlu-Gln-Phe-Phe-Gly-Leu-Met_.NH₂ 

Relevant articles and documents

Method and composition for treating IgE-mediated allergies

The present invention relates to a method and preparations for reducing IgE antibodies to allergens in allergic subjects wherein substance P and an allergen or fragments of allergens or haptens acting as allergens are administered together to the allergic subjects. The method can be used to treat humans and animals including dogs, cats, horses and subhuman primates.